0001193125-26-211943
SEC filingQ1 reflected sharp revenue normalization from prior COVID programs alongside deeper losses from pipeline investments, partially offset by cash preservation via collections and cost discipline, underscoring need for additional capital to sustain long-term plans.
Arcturus Therapeutics reported challenging Q1 2026 financials marked by revenue normalization following peak COVID-related contributions. Revenue fell 93% to $2.1 million from $29.4 million in Q1 2025, primarily due to lower manufacturing costs related to LUNAR-COVID and BARDA, alongside reduced clinical trial expenses for that program, as these collaborations mature and KOSTAIVE commercializes independently. This topline pressure drove operating income deeper into loss territory at -$28.9 million, a 72% worsening from -$16.8 million prior year, with operating margin at -1,404%. Net income followed suit to -$27.0 million or -$0.95 diluted EPS from -$14.1 million or -$0.52, as the revenue shortfall overwhelmed expense controls.
Expense management provided some offset, with declines tied to reduced share-based compensation and payroll/benefits from headcount reductions, alongside a strategic shift toward later-stage programs where early-stage and discovery expenses are expected to decrease. Cash flow dynamics improved notably: net cash used in operations narrowed to -$19.4 million from -$35.1 million, driven by enhanced accounts receivable collections that curbed outflows. Free cash flow matched at -$19.4 million with zero capital expenditures, versus $137 thousand prior year, reflecting disciplined capital allocation amid operational tightening. Interest income also dipped due to lower rates and cash balances.